Stereotaxis, Inc. (STXS)

Over the past six months, Stereotaxis' stock has decreased by approximately 30.2%, with a 52-week trading range between $1.74 and $3.59. In November 2025, Stereotaxis reported its third-quarter financial results and announced FDA clearance for its GenesisX robotic system. In January 2026, the MAGiC catheter received FDA approval. In March 2026, Stereotaxis held its Q4 2025 earnings conference call. In April 2026, Stereotaxis announced FDA clearance and the launch of its Synchrony system, a definitive agreement to acquire Robocath, and the first successful procedures in the United States using its MAGiC catheter for complex congenital heart disease and severe cardiac arrhythmia patients.

Stereotaxis experiences demand seasonality for its products and services, noting "summer seasonality in procedure volumes," which can impact recurring revenue in the third quarter.

Stereotaxis, Inc. is an American medical technology company specializing in robotic systems for interventional laboratories. The company's core business is its Robotic Magnetic Navigation (RMN) technology, designed to enhance minimally invasive endovascular procedures. Major products include the Genesis RMN System, GenesisX RMN System, Odyssey Solution, MAGiC Catheter, MAGiC Sweep, Synchrony System, SynX, QuikCAS, iCONNECT, V-CAS devices, and interventional devices under the Map-iT and EMAGIN brands. The GenesisX system aims to improve accessibility by reducing installation time. The Odyssey Solution is an integrated information solution for managing procedures. The MAGiC Catheter is a robotically navigated magnetic ablation catheter. The Synchrony system is a digital cath lab technology, and SynX is a cloud-based application for remote connectivity.

Stereotaxis, Inc. is headquartered in St. Louis, Missouri, USA, and has a global presence in the US, Europe, and China. Its robotic systems are installed in hospitals across North America, Europe, the Middle East, and Asia-Pacific, and its technology has been used in over 100,000 procedures worldwide.

In the past year, Stereotaxis' brand reputation has been positively impacted by FDA clearances, the Synchrony System launch, and the Robocath acquisition. The FDA clearance of the MAGiC ablation catheter and its successful use in the United States for complex congenital heart disease cases have been significant. The FDA clearance and launch of the Synchrony system also contribute positively to the company's reputation. The announced acquisition of Robocath is expected to create a more complete robotic surgical platform, potentially enhancing Stereotaxis' market position.

Stereotaxis, Inc. has a mix of institutional and individual owners. Major institutional owners include DAFNA Capital Management LLC, Lagoda Investment Management, L.P., BlackRock, Inc., Vanguard Group Inc, Arbiter Partners Capital Management LLC, Geode Capital Management, Llc, Essex Investment Management Co Llc, Warberg Asset Management LLC, Prescott Group Capital Management, L.l.c., State Street Corp, Joe E. Kiani, Paul J. Isaac, Fred A. Middleton, Bank of New York Mellon Corp, Sequoia Financial Advisors LLC, Cherry Creek Investment Advisors Inc., Bridgeway Capital Management LLC, Schonfeld Strategic Advisors LLC, Abel Hall LLC, Equitable Holdings Inc., Price T Rowe Associates Inc. MD, Royal Bank of Canada, Barclays PLC, Marshall Wace LLP, Wells Fargo & Company MN, SEI Investments Co., Manulife Financial Corp., Polar Capital Holdings Plc, and Redmile Capital Offshore II Master Fund, Ltd. Major individual owners include Nathan Fischel, Joe E. Kiani, Paul J. Isaac, and Fred A. Middleton; Nathan Fischel is the largest individual shareholder, owning 58.38% of the company's shares.